Publication Name	World Journal of Clinical Cases
Manuscript ID	71711
Country	China

Received	2021-09-19 12:33
Peer-Review Started	2021-09-19 12:34
To Make the First Decision
Return for Revision	2021-12-10 01:31
Revised	2021-12-19 05:23
Second Decision	2022-04-21 02:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-04-22 17:14
Articles in Press	2022-04-22 17:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-05-10 08:48
Publish the Manuscript Online	2022-06-02 10:05

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Mei Liu, Cheng Luo, Zong-Zhou Xie and Xun Li
ORCID	Author(s) ORCID Number Mei Liu http://orcid.org/0000-0002-8863-6577 Cheng Luo http://orcid.org/0000-0001-9275-8772 Zong-Zhou Xie http://orcid.org/0000-0002-1533-7189 Xun Li http://orcid.org/0000-0002-1663-170X
Funding Agency and Grant Number
Corresponding Author	Xun Li, MD, Chief Physician, Department of Medical Oncology, Haikou People's Hospital, 43 Renmin Avenue, Haikou 570100, Hainan Province, China. 1984661032@qq.com
Key Words	Gastric hepatoid adenocarcinoma; Serum; Immunotherapy; Targeted therapy; Chemotherapy; Case report
Core Tip	We report a rare case of gastric hepatoid adenocarcinoma in a patient who underwent general chemotherapy that failed. However, pembrolizumab and bevacizumab combination chemotherapy was successful. The overall survival was 16 mo, and the main adverse reaction was tolerable. The patient died of intestinal infection rather than tumor progression.
Publish Date	2022-06-02 10:05
Citation	Liu M, Luo C, Xie ZZ, Li X. Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report. World J Clin Cases 2022; 10(16): 5420-5427
URL	https://www.wjgnet.com/2307-8960/full/v10/i16/5420.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i16.5420

Full Article (PDF)	WJCC-10-5420.pdf
Full Article (Word)	WJCC-10-5420.docx
Manuscript File	71711_Auto_Edited_LM.docx
Answering Reviewers	71711-Answering reviewers.pdf
Audio Core Tip	71711-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	71711-Conflict-of-interest statement.pdf
Copyright License Agreement	71711-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	71711-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	71711-Language certificate.pdf
Peer-review Report	71711-Peer-review(s).pdf
Scientific Misconduct Check	71711-Bing-Ma YJ-2.png
Scientific Editor Work List	71711-Scientific editor work list.pdf